Inside the research

Elanco Animal Health Incorporated

ELAN Research profile · latest available data

Price overview

$22.31

▼ -0.04 (-0.2%)

52w hi$26.84
52w lo$18.92
Vol6.45M
As of25 Sep 2026

The Verdict

Hold

Our score -0.12

Short-0.36
Medium+0.03
Long+0.05

computed 2026-09-27

Key fundamentals

Elanco Animal Health Incorporated

Healthcare · Drug Manufacturers - Specialty & Generic

Market cap$11.14B
Enterprise value$14.85B
Forward P/E17.36x
EV / EBITDA14.75x
P / S (ttm)2.22x
Profit margin-4.0%
Return on equity-3.0%
Revenue growth+10.2%
Earnings growth+440.5%
Debt / equity64.25

Layer Breakdown

LayerRawContribution
Fundamental+0.16
Sector+0.08
Technical-0.05
Earnings+0.00
Sentiment-0.33

macro × 1.00 · 2026-09-27

Business overview

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. The company offers pet health products, such as parasiticides, vaccines, and therapeutics that protect pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks; prescription parasiticide products, an over-the-counter treatments for the prevention and elimination of fleas and ticks under the Credelio Family, Interceptor Plus, Drontal family, and Drontal Plus; vaccines portfolio that provides differentiated prevention coverage for a number of important pet health risks; and therapeutics portfolio for the treatment of pain, otitis, cardiovascular, and dermatology indications, as well as osteoarthritis for dogs and cats under the Galliprant trademark. It also provides farm animal products that help farmers improve animal health and wellbeing, and raise livestock, such as cattle, swine, and poultry. In addition, the company offers medicated feed additives, injectable antibiotics, vaccines, insecticides and enzymes, and others under the Rumensin, Baytril, and Experior trademarks for cattle; and under the Maxiban and Monteban trademarks for the control and prevention of intestinal disease in poultry. Further, it offers other pet health products for cats and dogs under the Atopica, Milbemax, Onsior, and Tru Family trademarks; and other farm animal products for poultry, cattle, and swine under the AviPro, Catosal, Denagard, Hemicell, Pulmotil, and Surmax tradmarks. The company sells its products to third-party distributors and independent retailers; and directly to farm animal producers and veterinarians. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Indianapolis, Indiana.

United States · www.elanco.com

Risk Metrics

Beta vs SPX1.31
Corr SPX0.45
Annual vol47.1%
Annual ret+33.8%
Sharpe0.72
Max DD-44.9%

Window: 504 trading days (504 obs)

Analyst Coverage

Mean PT$29.86
High / Low$32.00 / $24.00
Median$30.00
Analysts14
Strong Buy4
Buy11
Hold2
Sell0
Strong Sell0

Recent rating actions

2026-05-07JP Morgan→ Overweight
2026-05-07Citigroup→ Buy
2026-04-15Citigroup→ Buy
2026-02-25Morgan Stanley→ Equal-Weight
2026-02-25Keybanc→ Overweight
2026-02-24Leerink Partners→ Outperform

Material Events

DateEvent8-K
2026-08-05Earnings Release, Exhibitsread
2026-05-27Shareholder Voteread
2026-05-06Earnings Release, Exhibitsread
2026-02-24Earnings Release, Exhibitsread
2026-01-12Reg FD Disclosure, Exhibitsread
2025-12-09Restructuring, Reg FD Disclosure…read
2025-11-05Earnings Release, Exhibitsread
2025-11-03Material Agreement, Material Obligation…read
2025-08-07Earnings Release, Exhibitsread
2025-06-26Material Agreement, Material Obligation…read
2025-05-28Officer / Director Change, Reg FD Disclosure…read
2025-05-21Shareholder Voteread

Insider Trades

DateInsiderRoleActionSharesValue
2026-08-12Harrington Michael JDirectorBuy5.00K$109.10K
2026-08-07VanHimbergen Robert MOfficer, EVP and CFOBuy4.20K$96.93K
2026-08-07Herendeen PaulDirectorBuy10.00K$236.85K

Flow & Concentration

Insider 180d net$442.88K
Insider buys / sells3 / 0
Insider biasNeutral
13F holders0
Top-5 share0.0%
HHI0 (—)

SEC Filings

DateFormDoc
2026-08-134view
2026-08-104view
2026-08-104view
2026-08-104view
2026-08-104view
2026-08-058-Kview
2026-08-0510-Qview
2026-07-284view
2026-07-284view
2026-07-284view
2026-07-144view
2026-07-144view
2026-07-144view
2026-07-094view
2026-07-024view

The Long Run

FY 2018–2025 · 8 years

LineLatestCAGRTrend
Revenue$4.42B+6.3%
Net income$338.00M+97.7%
Cash from ops$271.00M-8.0%

Indices

S&P MidCap 400

Recent Sessions

DateOpenHighLowCloseVol
Sep 25$22.35$22.72$22.10$22.316.45M
Sep 24$22.59$22.63$21.75$22.357.64M
Sep 23$22.82$23.39$22.51$22.575.34M
Sep 22$22.53$23.18$22.51$22.935.61M
Sep 21$22.58$22.58$22.17$22.434.61M

Understand the score. Research layers are inputs to a model, and the available data has limits.

Read the methodology →